Irinotecan Liposome Injection

The FDA approved irinotecan liposome as part of a first-line regimen for the treatment of metastatic pancreatic adenocarcinoma.

In a video interview with Healio, Cecilia Monge, MD, MPH, FACP, from the NCI Center for Cancer Research at NIH, talked about the NAPOLI 3 trial data presented at ASCO Gastrointestinal Cancers Symposium.

In a video interview, Benjamin Schlechter, MD, talked about a “fascinating, compelling and important study” that looked at liposomal irinotecan injection regimen vs. nab-paclitaxel and gemcitabine in metastatic pancreatic cancer.

Irinotecan liposome injection combined with 5-FU/leucovorin and oxaliplatin prolonged OS compared with nab-paclitaxel and gemcitabine as initial treatment for patients with metastatic pancreatic ductal adenocarcinoma, study results showed.

In this edition, lung cancer screening critically low across the U.S, first in-human CRISPR test with gene replacement, racial and economic segregation linked to higher cancer mortality rates, and more.

An irinotecan liposome injection regimen improved OS compared with standard chemotherapy among untreated patients with metastatic pancreatic ductal adenocarcinoma, according to the agent’s manufacturer.

In this edition, lung cancer risk is high among smokers for whom screening is not recommended; the role of circulating tumor DNA in lung cancer detection and treatment is 'exciting' for field; a subset of patients with lung cancer have poor response to COVID-19 vaccines, and more.

Irinotecan liposomal injection as second-line treatment of small cell lung cancer failed to extend OS compared with topotecan, according to the agent’s manufacturer.

The FDA granted fast track designation to irinotecan liposome injection for treatment of certain patients with small cell lung cancer, according to the agent’s manufacturer.